INmune Bio Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
INMB Nasdaq 2830 www.inmunebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for INmune Bio Inc.

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ - Jun 25th, 2026 5:00 am
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB - Jun 23rd, 2026 6:00 am
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial - Jun 2nd, 2026 6:00 am
INmune Bio (INMB) Q4 2025 Earnings Transcript - Jun 1st, 2026 3:15 pm
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform - May 15th, 2026 6:00 am
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease - May 14th, 2026 6:00 am
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point - May 13th, 2026 6:00 am
INmune Bio (INMB) Q1 2026 Earnings Transcript - May 8th, 2026 8:30 am
INmune Bio, Inc. Q1 2026 Earnings Call Summary - May 8th, 2026 6:30 am
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update - May 7th, 2026 2:00 pm
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases - May 5th, 2026 2:00 pm
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th - Apr 30th, 2026 6:00 am
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models - Apr 16th, 2026 6:00 am
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely - Apr 1st, 2026 5:09 am
INmune Bio, Inc. Q4 2025 Earnings Call Summary - Mar 31st, 2026 6:30 am
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Mar 30th, 2026 9:01 pm
INmune Bio Inc. Announces 2025 Results and Provides Business Update - Mar 30th, 2026 2:00 pm
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - Mar 24th, 2026 6:00 am
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease - Mar 19th, 2026 6:00 am
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar - Feb 23rd, 2026 7:25 am